Evaluation of the Safety and Efficacy of ELA026 in Patients With Secondary Hemophagocytic Lymphohistiocytosis
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of
excessive immune activation. ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody
designed to reduce the myeloid and T cells driving the inflammation. The purpose of this
study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in
adult and adolescent patients with secondary hemophagocytic lymphohistiocytosis.